You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

46 Results
Guidelines and Advice
Status: Archived
ID: DILung
Apr 2012
Guidelines and Advice
Status: Current
ID: GL-C50-02
Jan 2012
Guidelines and Advice
Status: Current
ID: GL-C50-29
Mar 2012
Guidelines and Advice
Status: Current
Dec 2012
Guidelines and Advice
Status: Education and Information
Dec 2012
Guidelines and Advice
Status: Current
Version: 2
Mar 2022
Guidelines and Advice
Status: Current
Version: 2
Mar 2022
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    gilteritinib - Relapsed or Refractory FLT3-mutated acute myeloid leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
gilteritinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2022
Regimen
Cancer Type:
Hematologic, 
Leukemia - Hairy Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
vemURAFenib (Unfunded),
riTUXimab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2022
Guidelines and Advice
Status: Current
ID: GL 16-3
Version: 3
Mar 2022

Pages